CRDF earnings: real EPS beat/miss history, analyst consensus Buy, P/E -1.28. Updated 2026-07-23.
Cardiff Oncology (CRDF) Research Hub
Cardiff Oncology (CRDF) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.21 USD (+15.24%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.28, market cap 0.06B. This hub links to the full technical, earnings and options research available for CRDF.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.21 USD (+15.24%) |
| 52-week range | 0.757 USD – 1.6 USD |
| Trend regime | Range |
| 14-day RSI | 63.3 (Bullish) |
| Trailing P/E | -1.28 |
| Market cap | 0.06B |
| Dividend yield | 0.00% |
Available research for CRDF
Covered Call on CRDF: how it works, illustrative setup around the real 1.21 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CRDF: how it works, illustrative setup around the real 1.21 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CRDF: how it works, illustrative setup around the real 1.21 USD price, max profit/loss, breakeven and when to use it. Educational.
CRDF technical analysis: range, last 1.21 USD, RSI 63.3, 52w range 0.757 USD–1.6 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CRDF in?
Cardiff Oncology (CRDF) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CRDF in an uptrend or downtrend?
As of 2026-09-11, CRDF is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CRDF's trailing P/E ratio?
CRDF's trailing P/E is -1.28, with a market cap of 0.06B. See the earnings research page for full valuation detail.